Shih Ie-Ming, Kurman Robert J
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.
Clin Cancer Res. 2005 Oct 15;11(20):7273-9. doi: 10.1158/1078-0432.CCR-05-0755.
Ovarian borderline (low malignant potential) tumors are a puzzling group of neoplasms that do not fall neatly into benign or malignant categories. Their behavior is enigmatic, their pathogenesis unclear, and their clinical management controversial, especially for serous borderline tumors (SBT), the most common type of ovarian borderline tumor. Clarifying the nature of borderline tumors and their relationship to invasive carcinoma has puzzled investigators since the category was created over 30 years ago. Much of the confusion and controversy concerning these tumors is due to a lack of understanding of their pathogenesis and an absence of a model for the development of ovarian carcinoma. This review summarizes recent molecular studies of ovarian borderline tumors with special emphasis on the role of SBT in tumor progression and its relationship to ovarian serous carcinoma.
卵巢交界性（低恶性潜能）肿瘤是一类令人困惑的肿瘤，它们难以简单地归为良性或恶性类别。其行为难以捉摸，发病机制尚不清楚，临床管理存在争议，尤其是对于最常见的卵巢交界性肿瘤类型——浆液性交界性肿瘤（SBT）而言。自30多年前该类别创建以来，明确交界性肿瘤的性质及其与浸润性癌的关系一直困扰着研究人员。关于这些肿瘤的许多困惑和争议源于对其发病机制缺乏了解以及缺乏卵巢癌发生发展的模型。本综述总结了卵巢交界性肿瘤的近期分子研究，特别强调了SBT在肿瘤进展中的作用及其与卵巢浆液性癌的关系。
